Dr. Friba Nurmukhamma | Medicine | Best Researcher Award

Dr. Friba Nurmukhamma | Medicine | Best Researcher Award

Khoja Akhmet Yassawi International Kazakh-Turkish University | Kazakhstan

Dr. Friba NurmukhammadNasrullakyzy is a cardiologist, senior researcher, and PhD scholar specializing in cardiovascular pathology, with a particular focus on coronary artery disease (CAD), stenting, and post-coronary artery bypass grafting (CABG) outcomes. Her research explores the mechanisms of high residual platelet reactivity (HRPR) and dyslipidemia, contributing to improved treatment algorithms and predictive models aimed at reducing mortality in patients with complex cardiovascular conditions. Dr. Friba’s innovative work integrates clinical insights with advanced diagnostic methodologies and personalized therapeutic approaches, emphasizing non-statin therapies, platelet reactivity modulation, and functional diagnostics in cardiology. She has authored multiple peer-reviewed publications indexed in Scopus and other scientific databases, reflecting a growing international research presence. Her Scopus h-index is 3, and her research impact is further supported by citations across both Scopus and Google Scholar databases. Dr. Friba’s current projects involve developing mortality prediction scales and individualized treatment algorithms for patients with HRPR, aiming to advance precision medicine in cardiology. Her scientific contributions underscore her commitment to translational cardiovascular research and her role in fostering evidence-based practices within clinical cardiology.

Profile

Scopus | ORCID

Featured Publications

Mussagaliyeva, A., Zhangelova, S., Danyarova, L., Nurmukhammad, F., Kapsultanova, D., Sakhov, O., Rustamova, F., Sugraliyev, A., & Akhmentayeva, D. (2025). Residual platelet reactivity and dyslipidemia in post-CABG patients undergoing repeat revascularization: Insights from Kazakhstan. Diseases, 13(11), 365.

Nurmukhammad, F. N., Zhangelova, S. B., & Kapsultanova, D. A. (2025). Non-statin therapy in patients with elevated LDL-C and high platelet reactivity: A narrative review. Medical Journal of Malaysia, 80(2), 258–265.

Zhangelova, S. B., Nurmukhammad, F. N., & Nurdinov, N. (2023). High residual platelet reactivity as a predictor of atherothrombosis in patients with coronary heart disease. Science and Healthcare, 25(3), 25–31.

Mussagaliyeva, A., Zhangelova, S., Nurmukhammad, F., & Kapsultanova, D. (2025). Residual platelet reactivity and dyslipidemia in post-CABG patients: Preprint insights from Kazakhstan. Preprints, 2025(09), 2498.

Ms. tianyu zhou | Health Sciences | Best Researcher Award

Ms. tianyu zhou | Health Sciences | Best Researcher Award

Editor, Disease Control And Prevetion, China

Zhou Tianyu is a dedicated researcher in the field of pharmacology, specializing in drug safety evaluation and molecular pharmacology. Born in Weinan City, Shaanxi Province, China, she has an extensive background in pharmacy and biomedical research. With a strong passion for scientific exploration, she has actively contributed to multiple national research projects, focusing on drug mechanisms, adverse drug reactions, and bioinformatics analysis. Her research expertise includes PCR, Western blot, flow cytometry, and serum pharmacology, making her proficient in both experimental operations and data analysis.

Publication Profile

Scopus

🎓 Education

Zhou Tianyu earned her Master’s degree in Pharmacy from Shaanxi University of Chinese Medicine (2021-2024), where she studied advanced courses such as Pharmacology, Medicinal Chemistry, and Molecular Biology. She also completed her undergraduate studies at the same institution (2017-2021), gaining in-depth knowledge of Organic Chemistry, Analytical Chemistry, and Natural Drug Chemistry. Her academic journey has equipped her with strong theoretical and practical skills in pharmaceutical sciences.

🏆 Experience

Throughout her research career, Zhou Tianyu has been involved in numerous prestigious projects. She contributed to the study of donkey-hide gelatin’s role in regulating alveolar macrophage transformation in chronic obstructive pulmonary disease (COPD) based on the TLR/NF-κB/L-arginine signaling axis. She successfully built a COPD mouse model and conducted inflammation studies using RAW264.7 cells. Additionally, she worked on mining adverse drug reactions from the FAERS database, leading to a published article in Scientific Reports. Her industrial experience includes internships at Xi’an Zhengda Pharmaceutical Co., Ltd. and Beijing Union Jianhao Pharmaceutical Technology Development Co., Ltd., where she specialized in drug processing, safety evaluation, and archives management.

🏅 Awards and Honors

Zhou Tianyu’s academic excellence has been recognized with the Third-Class Postgraduate Scholarship (2022). She has also actively participated in social service and professional activities, earning the title of “Excellent Volunteer” in the “Serving the Society, Caring for Health” Free Clinic (2017-2018) and at the 13th Shaanxi Province Games (2018). Furthermore, she secured third place in the “Shennong Painting Hundreds of Herbs—Chinese Medicine Painting Exhibition” and held leadership roles in her university’s Youth League Organization.

🔍 Research Focus

Her research interests include drug safety evaluation, bioinformatics, network pharmacology, and molecular mechanisms of drug action. She has contributed significantly to studying the anti-pulmonary fibrosis effects of Prismatomeris connata extract using spatially resolved metabolomics. She also explored hepatotoxicity mechanisms in Polygonum multiflorum through network toxicology. Her expertise extends to allergy research, where she investigated inflammatory mediator responses in RBL2H3 cells.

📝 Conclusion

Zhou Tianyu is an ambitious and skilled researcher with a strong foundation in pharmacology, data analysis, and experimental methodologies. Her ability to integrate bioinformatics with laboratory research has contributed to high-impact publications and drug safety assessments. With her keen analytical mind and collaborative nature, she continues to explore innovative pharmaceutical solutions while striving for excellence in drug research and evaluation.

📚 Publications

Spatially resolved metabolomics visualizes heterogeneous distribution of metabolites in lung tissue and the anti-pulmonary fibrosis effect of Prismatomeris connata extract

Unraveling the mechanism of ethyl acetate extract from Prismatomeris connata Y. Z. Ruan root in treating pulmonary fibrosis: insights from bioinformatics, network pharmacology, and experimental validation

 Inegrated spatially resolved metabolomics and network toxicology to investigate the hepatotoxicity mechanisms of component D of Polygonum multiflorum Thunb.